EUVIMEDEUVIMED entdecken
Crossref

Annual Report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual Patient Report for 2022 and Annual Treatment Report for 2017

Hiroaki Kajiyama, Satoshi Tamauchi iD, Fumiaki Takahashi, Toyomi Satoh iD, Board Members of the 2025 Committee on Gynecologic Oncology of the Japan Society of Obstetrics and Gynecology

Journal of Obstetrics and Gynaecology Research · 2025-11 · 51 (11)

DOI: 10.1111/jog.70124 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Obstetrics and Gynaecology Research, online erschienen am 29.10.2025. Verfasst von Hiroaki Kajiyama und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan. Hauptthemen laut MEDLINE: Genital Neoplasms, Female, Registries, Medical Oncology. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To provide information including the trend of gynecological malignancies in Japan, we hereby present the Annual Patient Report for 2022 and the Annual Treatment Report for 2017, on the outcomes of patients who started treatment in 2017.

Methods

The Japan Society of Obstetrics and Gynecology maintains an annual tumor registry, where information on gynecological malignancies from various participating institutions is gathered. The data of patients whose treatment with gynecologic malignancies was initiated in 2022 were analyzed retrospectively. Survival of the patients who started treatment with cervical, endometrial, and ovarian cancer in 2017 was analyzed by using the Kaplan–Meier, log–rank, and Wilcoxson tests.

Results

Treatment was initiated in 2022 for 8039 patients with cervical cancer, 14 518 with endometrial cancer, 8524 with ovarian, tubal, and peritoneal cancer, 2360 with ovarian borderline tumors, and with the others (270 vulvar cancer, 179 vaginal cancer, 539 uterine sarcoma, 48 uterine adenosarcoma, 158 trophoblastic diseases). This clinicopathological information was summarized as the Patient Annual Report. The 5‐year survival rates of the patients who initiated treatment in 2017 were as follows. For cervical cancer, the rates were 93.0%, 76.1%, 59.5%, and 28.3% for Stages I, II, III, and IV, respectively. For endometrial cancer, the rates were 94.9%, 88.8%, 72.7%, and 28.9% for Stages I, II, III, and IV, respectively. For ovarian cancer, the rates were 91.7%, 76.6%, 54.4%, and 45.2% for Stages I, II, III, and IV, respectively.

Conclusion

The annual tumor report is an important survey that provides knowledge on gynecological malignancy trends in Japan.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genital Neoplasms, FemaleRegistriesMedical OncologyHumansFemaleJapanSocieties, MedicalGynecologyMiddle AgedAdultAgedObstetricsAnnual Reports as TopicRetrospective StudiesSurvival Rate

Stichwörter der Autor:innen

Japanannual reportcervical cancerendometrial cancergynecologic cancerovariantubal and peritoneal cancer

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Department of Information Science, Iwate Medical University, Yahaba, Japan.
  • Department of Obstetrics and Gynecology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.

ORCID-Profile: Satoshi Tamauchi, Toyomi Satoh

Zitieren

APA

Kajiyama, H., Tamauchi, S., Takahashi, F., Satoh, T., & Board Members of the 2025 Committee on Gynecologic Oncology of the Japan Society of Obstetrics and Gynecology (2025). Annual Report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual Patient Report for 2022 and Annual Treatment Report for 2017. Journal of Obstetrics and Gynaecology Research, 51(11). https://doi.org/10.1111/jog.70124

Vancouver

Kajiyama H, Tamauchi S, Takahashi F, Satoh T, Board Members of the 2025 Committee on Gynecologic Oncology of the Japan Society of Obstetrics and Gynecology. Annual Report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual Patient Report for 2022 and Annual Treatment Report for 2017. Journal of Obstetrics and Gynaecology Research. 2025;51(11). doi:10.1111/jog.70124

BibTeX
@article{Kajiyama2025,
  author = {Kajiyama, Hiroaki and Tamauchi, Satoshi and Takahashi, Fumiaki and Satoh, Toyomi and Board Members of the 2025 Committee on Gynecologic Oncology of the Japan Society of Obstetrics and Gynecology, Board Members of the 2025 Committee on Gynecologic Oncology of the Japan Society of Obstetrics and Gynecology},
  title = {Annual Report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual Patient Report for 2022 and Annual Treatment Report for 2017},
  journal = {Journal of Obstetrics and Gynaecology Research},
  year = {2025},
  volume = {51},
  number = {11},
  doi = {10.1111/jog.70124}
}
Kostenlos starten →